ButCoIns GUTS: - Gut Immunological Effects of Resistant Starch and Arabinoxylans in Subjects With Metabolic Syndrome

Sponsor
University of Aarhus (Other)
Overall Status
Completed
CT.gov ID
NCT01618526
Collaborator
Aarhus University Hospital (Other)
22
1
2
37
0.6

Study Details

Study Description

Brief Summary

Dietary fibers including resistent starch, RS, and arabinoxylans, AX, have been shown to have anti-inflammatory effects and to change the composition of the faecal micro flora in the colon.

In this unblinded dietary intervention cross-over study 20 subjects with metabolic syndrome are randomized to two types of diet intervention: a low and a high fiber diet. The participants are subjected to endoscopy before and in the end of each intervention.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Western Style Diet
  • Dietary Supplement: Healthy Carbohydrate Diet
N/A

Detailed Description

Dietary fibers including resistent starch, RS, and arabinoxylans, AX, have been shown to have anti-inflammatory effects and to change the composition of the faecal micro flora in the colon.

In this unblinded dietary intervention cross-over study 20 subjects with metabolic syndrome are subjected to two types of diet intervention:

  1. a western style diet, WSD, with a low fiber content and

  2. a healthy carbohydrate diet, HCD, a high fiber diet. Between the two 4-weeks diet is a wash-out period of four to eight weeks. The participants are subjected to endoscopy with tissue samples before and in the end of each intervention. Fecal and blood samples will be collected at the same time.

We hypothesize that a high content of resistent starch and arabinoxylans increases colonic butyrate concentration, changes colon's mucosal immune system and the microbiota.

A small pilot study will be carried out on 12 healthy volunteers in order to obtain a reference to participants with metabolic syndrome. The healthy volunteers will be subjected to an endoscopy but no dietary intervention.

Study Design

Study Type:
Interventional
Actual Enrollment :
22 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
ButCoIns GUTS: - Gut Immunological Effects of Resistant Starch and Arabinoxylans in Subjects With Metabolic Syndrome
Study Start Date :
Apr 1, 2012
Actual Primary Completion Date :
Dec 1, 2013
Actual Study Completion Date :
May 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Healthy Carbohydrate Diet

4 weeks of intervention with a diet rich in Arabinoxylans and Resistent Starch

Dietary Supplement: Healthy Carbohydrate Diet
Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers ( Arabinoxylans and Resistent Starch) compared with Western Style Diet with low content of dietary fibers

Placebo Comparator: Western Style Diet

4 weeks of intervention with a diet with low content of Resistent Starch and Arabinoxylans.

Dietary Supplement: Western Style Diet
Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers (Arabinoxylans and Resist Starch) compared with a Western Style Diet with a low content of dietary fibers.

Outcome Measures

Primary Outcome Measures

  1. Feces-short chain fatty acids [Baseline and 4 weeks]

    Concentration of short chain fatty acids

Secondary Outcome Measures

  1. A change in gut microbiome evaluated by 16 S-RNA analysis [Baseline and 4 weeks]

  2. Change in Nuclear Factor-kappa B (NF-кB) described by gene expression analysis. [Baseline and 4 weeks]

  3. Change in production of pro inflammatory cytokines on mucosal level (IFN-γ, TNF-α, IL-17). [Baseline and 4 weeks]

  4. Change in production of regulatory cytokines on mucosal level and in peripheral blood mononuclear cell (IL-22, IL-10 TNF-β). [Baseline and 4 weeks]

  5. Activation of T-cells in mucosa described by reduced expression of CD25 and CD69. [Baseline and 4 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria: At least 3 out of 5 following criteria:
  • Central obesity (Female > 80 cm, Male > 94 cm)

  • HDL cholesterol (Female < 1,03 mmol/L, Male < 1,29 mmol/L)

  • Bloodpressure (> 130/85 mmHg)

  • Fasting Blood Glucose > 5,6 mmol/L

Exclusion Criteria:
  • Diabetes

  • Gastrointestinal disease

  • Serious liver, heart or kidney disease

  • Anticoagulation treatment

  • Anaemia

  • Corticosteroid treatment

  • Waist circumference above 130 cm

  • Alcohol or drug addiction

  • Pregnancy or lactation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Aarhus University Aarhus Denmark 8000

Sponsors and Collaborators

  • University of Aarhus
  • Aarhus University Hospital

Investigators

  • Principal Investigator: Knud Erik Bach Knudsen, Professor, Aarhus University, Department of Animal Sciens

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Aarhus
ClinicalTrials.gov Identifier:
NCT01618526
Other Study ID Numbers:
  • V02062012
First Posted:
Jun 13, 2012
Last Update Posted:
May 29, 2015
Last Verified:
Aug 1, 2013
Keywords provided by University of Aarhus
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 29, 2015